Parallel Advisors’s Kindred Biosciences, Inc. KIN Stock Holding History

Parallel Advisors’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-109	Closed	-$1K	–	3397
2021 Q2	$1K	Buy	+109	New	+$634	﹤0.01%	2900
2020 Q3	–	Sell	-3,000	Closed	-$13K	–	2737
2020 Q2	$13K	Buy	3,000 +1,000	+50%	+$4.47K	﹤0.01%	1624
2020 Q1	$8K	Buy	2,000 +1,000	+100%	+$8.49K	﹤0.01%	1752
2019 Q4	$8K	Hold	1,000	–	–	﹤0.01%	1834
2019 Q3	$7K	Buy	+1,000	New	+$7.33K	﹤0.01%	1836
2018 Q2	–	Sell	-1,075	Closed	-$10.5K	–	2247
2018 Q1	$9K	Hold	1,075	–	–	﹤0.01%	1344
2017 Q4	$10K	Hold	1,075	–	–	﹤0.01%	1315
2017 Q3	$8K	Sell	1,075 -1,000	-48%	-$7.5K	﹤0.01%	1399
2017 Q2	$15K	Buy	2,075 +1,000	+93%	+$7.17K	﹤0.01%	1143
2017 Q1	$7K	Buy	+1,075	New	+$6.73K	﹤0.01%	1380

Other funds holding KIN

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Parallel Advisors's KIN Position: Q3 2021 in Review

Parallel Advisors sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 109 shares — an estimated $1K sold.

Parallel Advisors first reported a position in KIN in Q1 2017 and held it in 10 quarters. The position peaked at $15K in Q2 2017. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.

Parallel Advisors reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
Parallel Advisors sold 109 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $1K.
Parallel Advisors first reported a position in Kindred Biosciences, Inc. in Q1 2017 and held it in 10 quarters.
Parallel Advisors's Kindred Biosciences, Inc. position peaked at $15K in Q2 2017.
1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.

Based on Parallel Advisors's 13F filing for Q3 2021, filed 22 Oct 2021.